Nicolás Crisosto, Ph.D., Bárbara Echiburú, Ph.D., Manuel Maliqueo, Ph.D., Virginia Pérez, M.D., Amanda Ladrón de Guevara, M.D., Jessica Preisler, M.D., Fernando Sánchez, M.D., Teresa Sir-Petermann, Ph.D.
Volume 97, Issue 1 , Pages 218-224
To evaluate the ovarian function during early infancy in daughters of women with polycystic ovary syndrome (PCOS) treated with metformin throughout pregnancy (PCOSd+M), as a means to reduce androgen and insulin levels, compared with daughters of nontreated PCOS women (PCOSd−M) and daughters of women who belong to a healthy comparison group (HCd).
Descriptive and analytic study.
Unit of endocrinology and reproductive medicine.
Fifteen PCOSd+M, 23 PCOSd−M, and 35 HCd were studied at 2–3 months of age.
A GnRH analogue test was performed with determinations of gonadotropins, sex steroids, SHBG, and anti-Müllerian hormone (AMH).
Main Outcome Measure(s):
Differences in AMH levels between PCOSd+M, PCOSd−M and HCd.
AMH and peak E2 concentrations were significantly higher in PCOSd−M compared with HCd, whereas PCOSd+M exhibited AMH concentrations and peak E2 levels similar to those observed in HCd.
The improvement of the altered endocrine-metabolic environment of PCOS mothers reduces AMH levels in their daughters, which might reflect a decrease in their follicular mass.
Read the full text at: http://www.fertstert.org/article/S0015-0282(11)02668-9/fulltext